Mesenteric arteries from GK rats treated with losartan exhibited

Mesenteric arteries from GK rats treated with losartan exhibited (vs. untreated GK) 1) reduced nucleotide-induced contractions, 2) suppressed UTP-induced release of PGE(2) and PG(F2 alpha), 3) suppressed UTP-stimulated cPLA(2) phosphorylation, 4) normalized expressions of COX-2 and P2Y4 receptors, and 5) reduced superoxide BMS-777607 datasheet generation. Our data suggest that the diabetes-related enhancement of ATP-mediated vasoconstriction was due to P2Y receptor-mediated activation of the cPLA(2)/COX pathway

and, moreover, that losartan normalizes such contractions by a suppressing action within this pathway.”
“Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), blocks the alpha(2)-adrenergic autoreceptors

and heteroreceptors, which are responsible for controlling noradrenaline and 5-hydroxytryptamine (5-HT) release. Though preclinical and clinical studies have shown that mirtazapine exerts an anxiolytic action, its precise brain target sites remain unclear. In the present study, we investigated the brain area(s) in which mirtazapine exerts its anxiolytic-like effects on the expression of contextual conditioned freezing in rats. Mirtazapine (3 mu g/site) was directly injected into three brain structures, the median raphe nucleus (MRN), hippocampus and amygdala. Freezing behavior tests were carried out 10 min after injections. Our results showed that the intra-MRN injection of Panobinostat in vitro mirtazapine reduced

freezing significantly, whereas injections CYT387 into the hippocampus or the amygdala did not. In addition, the intra-MRN injection of mirtazapine did not affect locomotor activity. These results suggest that the anxiolytic-like effect of mirtazapine might be mediated by its action on the MRN. (C) 2013 Elsevier B.V. All rights reserved.”
“Purpose: To examine the safety of outpatient clinic simultaneous intravenous fundus fluorescein angiography (IVFA) and indocyanine green angiography (ICGA) in patients with any/all drug allergy history.\n\nMethods: In a single-center retrospective study conducted from February 2007 to March 2011, 390 consecutive outpatients with drug allergy history and 3426 patients without allergy history underwent simultaneous intravenous IVFA and ICGA. The detailed drug allergy history, the symptoms and time of the adverse reaction during simultaneous IVFA and ICGA were recorded in all the patients.\n\nResults: Of the 390 patients with drug allergy history who received IVFA and ICGA, 28 patients (7.2%) had an adverse reaction. In contrast, 145 of the 3426 patients (4.2%) without allergy history had an adverse reaction during simultaneous IVFA and ICGA. Statistical significance in the incidence (P = 0.008) and severity (P = 0.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>